341 related articles for article (PubMed ID: 26490656)
1. Fluorouracil, leucovorin and irinotecan associated with aflibercept can induce microscopic colitis in metastatic colorectal cancer patients.
Ghiringhelli F; Vincent J; Beltjens F; Bengrine L; Ladoire S
Invest New Drugs; 2015 Dec; 33(6):1263-6. PubMed ID: 26490656
[TBL] [Abstract][Full Text] [Related]
2. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.
Tabernero J; Van Cutsem E; Lakomý R; Prausová J; Ruff P; van Hazel GA; Moiseyenko VM; Ferry DR; McKendrick JJ; Soussan-Lazard K; Chevalier S; Allegra CJ
Eur J Cancer; 2014 Jan; 50(2):320-31. PubMed ID: 24140268
[TBL] [Abstract][Full Text] [Related]
3. The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of the Evidence.
Wade R; Duarte A; Simmonds M; Rodriguez-Lopez R; Duffy S; Woolacott N; Spackman E
Pharmacoeconomics; 2015 May; 33(5):457-66. PubMed ID: 25616671
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer.
Yoshino T; Yamazaki K; Yamaguchi K; Doi T; Boku N; Machida N; Onozawa Y; Asayama M; Fujino T; Ohtsu A
Invest New Drugs; 2013 Aug; 31(4):910-7. PubMed ID: 23179335
[TBL] [Abstract][Full Text] [Related]
5. Aflibercept for metastatic colorectal cancer: safety data from the Spanish named patient program.
Salgado Fernández M; Pérez Hoyos MT; Díaz de Corcuera I; Vidal Arbués A; García de la Torre M
Expert Opin Drug Saf; 2015 Aug; 14(8):1171-9. PubMed ID: 26076885
[TBL] [Abstract][Full Text] [Related]
6. Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial.
Ruff P; Van Cutsem E; Lakomy R; Prausova J; van Hazel GA; Moiseyenko VM; Soussan-Lazard K; Dochy E; Magherini E; Macarulla T; Papamichael D
J Geriatr Oncol; 2018 Jan; 9(1):32-39. PubMed ID: 28807738
[TBL] [Abstract][Full Text] [Related]
7. Safety and Management of Toxicity Related to Aflibercept in Combination with Fluorouracil, Leucovorin and Irinotecan in Malaysian Patients with Metastatic Colorectal Cancer.
Yusof MM; Abdullah NM; Sharial MM; Zaatar A
Asian Pac J Cancer Prev; 2016; 17(3):973-8. PubMed ID: 27039822
[TBL] [Abstract][Full Text] [Related]
8. Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302).
Lapeyre-Prost A; Pernot S; Sigrand J; Le Malicot K; Mary F; Aparicio T; Dahan L; Caroli-Bosc FX; Lecomte T; Doat S; Marthey L; Desrame J; Lepage C; Taieb J
Clin Colorectal Cancer; 2020 Dec; 19(4):285-290. PubMed ID: 32921581
[TBL] [Abstract][Full Text] [Related]
9. Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy.
Ruff P; Ferry DR; Lakomỳ R; Prausová J; Van Hazel GA; Hoff PM; Cunningham D; Arnold D; Schmoll HJ; Moiseyenko VM; McKendrick JJ; Ten Tije AJ; Vishwanath RL; Bhargava P; Chevalier S; Macarulla T; Van Cutsem E
Eur J Cancer; 2015 Jan; 51(1):18-26. PubMed ID: 25466509
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of aflibercept in combination with fluorouracil, leucovorin and irinotecan in the treatment of Asian patients with metastatic colorectal cancer.
Chong DQ; Manalo M; Imperial M; Teo P; Yong G; Ng M; Tan IB; Choo SP; Chua C
Asia Pac J Clin Oncol; 2016 Sep; 12(3):275-83. PubMed ID: 27075236
[TBL] [Abstract][Full Text] [Related]
11. Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study.
Pastorino A; Di Bartolomeo M; Maiello E; Iaffaioli V; Ciuffreda L; Fasola G; Di Costanzo F; Frassineti GL; Marchetti P; Antoniotti C; Leone F; Zaniboni A; Aprile G; Zilocchi C; Sobrero A; Bordonaro R
Clin Colorectal Cancer; 2018 Sep; 17(3):e457-e470. PubMed ID: 29605592
[TBL] [Abstract][Full Text] [Related]
12. Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP).
Riechelmann RP; Srimuninnimit V; Bordonaro R; Kavan P; Di Bartolomeo M; Maiello E; Cicin I; García-Alfonso P; Chau I; Fedyanin MY; Martos CF; Ter-Ovanesov M; Peeters M; Ko YJ; Yalcin S; Karthaus M; Aparicio J; Heinemann V; Picard P; Bury D; Drea E; Sobrero A
Clin Colorectal Cancer; 2019 Sep; 18(3):183-191.e3. PubMed ID: 31221542
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Aflibercept in Combination With Chemotherapy Beyond Second-Line Therapy in Metastatic Colorectal Carcinoma Patients: An AGEO Multicenter Study.
Auvray M; Tougeron D; Auclin E; Moulin V; Artru P; Hautefeuille V; Hammel P; Lecomte T; Locher C; Sickersen G; Coriat R; Lecaille C; Vernerey D; Taieb J; Pernot S
Clin Colorectal Cancer; 2020 Mar; 19(1):39-47.e5. PubMed ID: 31648924
[TBL] [Abstract][Full Text] [Related]
14. Risk-benefit Analysis of FOLFIRI Plus Ramucirumab/Aflibercept as a Third-line Treatment in Metastatic Colorectal Cancer.
Kimura M; Usami E; Teramachi H; Yoshimura T
Anticancer Res; 2021 Jun; 41(6):3091-3097. PubMed ID: 34083302
[TBL] [Abstract][Full Text] [Related]
15. Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours.
Van Cutsem E; Khayat D; Verslype C; Billemont B; Tejpar S; Meric JB; Soussan-Lazard K; Assadourian S; Cartot-Cotton S; Rixe O
Eur J Cancer; 2013 Jan; 49(1):17-24. PubMed ID: 22921183
[TBL] [Abstract][Full Text] [Related]
16. Aflibercept.
Ciombor KK; Berlin J; Chan E
Clin Cancer Res; 2013 Apr; 19(8):1920-5. PubMed ID: 23444216
[TBL] [Abstract][Full Text] [Related]
17. Aflibercept. Metastatic colorectal cancer: at least as poorly tolerated as bevacizumab.
Prescrire Int; 2014 Sep; 23(152):205. PubMed ID: 25325116
[TBL] [Abstract][Full Text] [Related]
18. Aflibercept: A Review in Metastatic Colorectal Cancer.
Syed YY; McKeage K
Drugs; 2015 Aug; 75(12):1435-45. PubMed ID: 26220913
[TBL] [Abstract][Full Text] [Related]
19. Posterior Reversible Encephalopathy Syndrome During Treatment with Aflibercept, 5-Fluorouracil, Leucovorin, and Irinotecan for Metastatic Colorectal Cancer.
Miaris N; Sgouros J; Gerolympou M; Spyropoulos B; Drakopoulos D; Gkoura S; Res H; Samantas E
J Gastrointest Cancer; 2019 Mar; 50(1):123-126. PubMed ID: 28660523
[No Abstract] [Full Text] [Related]
20. Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting.
Lambrechts D; Thienpont B; Thuillier V; Sagaert X; Moisse M; Peuteman G; Pericay C; Folprecht G; Zalcberg J; Zilocchi C; Margherini E; Chiron M; Van Cutsem E
Br J Cancer; 2015 Sep; 113(7):1027-34. PubMed ID: 26355232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]